On November 20th, the Medical Pricing and Tendering Procurement Guidance Center of the National Medical Insurance Administration announced the situation of 26 pharmaceutical companies rated as "particularly serious" and "severely" dishonest in various provinces, of which 23 were rated as "serious" and 3 were rated as "particularly serious". According to the credit evaluation catalog, pharmaceutical commercial bribery, tax related violations, monopolistic behavior, unfair pricing behavior, disruption of centralized procurement order, malicious breach of contract agreements and other behaviors that violate honesty and credibility are included in the scope of pharmaceutical pricing and procurement credit evaluation. This is the seventh issue of the price bidding credit evaluation "particularly serious" and "severe" dishonesty evaluation results released by the National Medical Insurance Bureau in November 2020 after the issuance of the "Operating Standards for Medical Price and Bidding Credit Evaluation (2020 Edition)" and "Discretionary Benchmark for Medical Price and Bidding Credit Rating (2020 Edition). Compared with the previous six installments, there were as many as 26 dishonest pharmaceutical companies this time (the previous maximum was the fifth installment, with a total of 11 dishonest companies, including 10 "serious" dishonest companies and 1 "particularly serious" dishonest company), and the dishonest behavior of bidding winning pharmaceutical companies has significantly increased. Before the introduction of the national centralized procurement system for drugs, there were some chaos in the field of drug procurement and sales, with the most typical manifestation being that commercial bribery became an important means for pharmaceutical companies to open up sales channels and expand sales. In addition, speculative practices such as bidding at low prices, arbitrarily reducing or even cutting off supply after winning the bid by pharmaceutical companies are not uncommon, and some pharmaceutical companies lack credibility. However, due to the lack of fundamental governance of this practice in the past, few pharmaceutical companies have been punished as a result, resulting in chaos such as drug "winning the bid dead" and the disappearance of a large number of cheap and good drugs. Drug centralized procurement can not only squeeze out the moisture of drug prices through methods such as "soul bargaining", but also help the industry reshuffle and establish new rules. It can be said that drug procurement is a great opportunity to address the chaos of drug purchase and sales. However, the current increase in dishonest behavior among pharmaceutical companies is also a source of concern. If the old disease recurs and other pharmaceutical companies follow suit, the drug procurement model will face the risk of breaking rules. Therefore, such dishonest behavior must not be tolerated. Especially with the deepening of relevant medical reforms and the continuous strengthening of medical anti-corruption efforts, pharmaceutical commercial bribery has significantly decreased. The current occurrence of pharmaceutical commercial bribery not only harms drug procurement, but also undermines the good situation of medical anti-corruption. Therefore, for behaviors such as selling with gold, it is even more important to provide head-on punishment through credit reporting and other means, so that dishonest individuals are restricted in the field of pharmaceutical purchasing. It should also be noted that in volume procurement, it is "quantity" and should belong to a two-way commitment. On the one hand, it is necessary to ensure the basic sales volume of drugs by including them in the medical insurance catalog, so that pharmaceutical companies can achieve small profits and quick sales, obtain substantial benefits, and thus exchange for a significant price reduction of drugs; On the other hand, pharmaceutical companies should also ensure that the winning drugs are supplied in sufficient quantities at the winning price. Any violations of contract agreements, such as reducing or even cutting off supply, should be punished as serious dishonesty. The past common methods of selective supply, random supply, and temporary cost increase demands for price increases should be eliminated. The centralized procurement of drugs has made many high priced drugs of the past extremely easy to obtain, therefore, for this type of purchase and sales